Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

  • Monti D
  • Mitchell E
  • Bazzan A
 et al. 
  • 3


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


BACKGROUND: Preclinical data support further investigation of ascorbic acid in pancreatic cancer. There are currently insufficient safety data in human subjects, particularly when ascorbic acid is combined with chemotherapy. METHODS AND FINDINGS: 14 subjects with metastatic stage IV pancreatic cancer were recruited to receive an eight week cycle of intravenous ascorbic acid (three infusions per week), using a dose escalation design, along with standard treatment of gemcitabine and erlotinib. Of 14 recruited subjects enrolled, nine completed the study (three in each dosage tier). There were fifteen non-serious adverse events and eight serious adverse events, all likely related to progression of disease or treatment with gemcitabine or erlotinib. Applying RECIST 1.0 criteria, seven of the nine subjects had stable disease while the other two had progressive disease. CONCLUSIONS: These initial safety data do not reveal increased toxicity with the addition of ascorbic acid to gemcitabine and erlotinib in pancreatic cancer patients. This, combined with the observed response to treatment, suggests the need for a phase II study of longer duration. TRIAL REGISTRATION: NCT00954525.

Author-supplied keywords

  • *Antineoplastic Combined Chemotherapy Protocols/tu
  • *Pancreatic Neoplasms/dt [Drug Therapy]
  • 0 (Quinazolines)
  • 0W860991D6 (Deoxycytidine)
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols/ae
  • Ascorbic Acid/ad [Administration & Dosage]
  • Ascorbic Acid/ae [Adverse Effects]
  • B76N6SBZ8R (gemcitabine)
  • DA87705X9K (Erlotinib Hydrochloride)
  • Deoxycytidine/aa [Analogs & Derivatives]
  • Deoxycytidine/ad [Administration & Dosage]
  • Deoxycytidine/ae [Adverse Effects]
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Erlotinib Hydrochloride
  • Female
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Neoplasm Staging
  • PQ6CK8PD0R (Ascorbic Acid)
  • Pancreatic Neoplasms/pa [Pathology]
  • Pulmonary Embolism/ci [Chemically Induced]
  • Quinazolines/ad [Administration & Dosage]
  • Quinazolines/ae [Adverse Effects]
  • Treatment Outcome

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • D A Monti

  • E Mitchell

  • A J Bazzan

  • S Littman

  • G Zabrecky

  • C J Yeo

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free